Stocks and Investing
Stocks and Investing
Fri, January 6, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, January 5, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Joseph Thome Downgraded (YMAB) to Hold on, Jan 5th, 2023
Joseph Thome of Cowen & Co., Downgraded "Y-mAbs Therapeutics, Inc." (YMAB) to Hold on, Jan 5th, 2023.
Joseph has made no other calls on YMAB in the last 4 months.
There are 7 other peers that have a rating on YMAB. Out of the 7 peers that are also analyzing YMAB, 3 agree with Joseph's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Alec Stranahan of "B of A Securities" Maintained at Hold with Increased Target to $6 on, Thursday, December 15th, 2022
- Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $8 on, Monday, October 31st, 2022
- David Nierengarten of "Wedbush" Downgraded from Buy to Hold and Held Target at $6 on, Monday, October 31st, 2022
These are the ratings of the 4 analyists that currently disagree with Joseph
- Etzer Darout of "BMO Capital" Maintained at Buy with Decreased Target to $12 on, Tuesday, November 1st, 2022
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $19 on, Monday, October 31st, 2022
- Tessa Romero of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $7 on, Monday, October 31st, 2022
- William Maughan of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $27 on, Monday, October 31st, 2022
Contributing Sources